

Serial No.: 08/450,437
Group Art Unit No.: 1207

Sub B4
A3

25. A method for the treatment and/or prophylaxis of pulmonary disorders (asthma, chronic obstructive pulmonary diseases -COPD-, airway hyperreactivity, cough), skin disorders and itch (for example, atopic dermatitis and cutaneous wheal and flare), neurogenic inflammation and CNS disorders (Parkinson's disease, movement disorders, anxiety), convulsive disorders, epilepsy, renal disorders, urinary incontinence, ocular inflammation, inflammatory pain, eating disorders (food intake inhibition), allergic rhinitis, neurodegenerative disorders (for example Alzheimer's disease), psoriasis, Huntington's disease, and depression in mammals, which comprises administering to the mammal in need of such treatment and/or prophylaxis an effective, pharmaceutically acceptable, and non-toxic amount of a compound of formula (I), or a solvate or salt thereof, as defined in claim 23.--.

REMARKS

This Amendment is made in response to the Official Action mailed December 16, 1996. A request for a three-month extension of time accompanies this Amendment. Claims 9, 10, 12 and 13 have been canceled without prejudice. Claims 1, and 2 have been amended. New claims 17 to 25 have been added. Accordingly, claims 1-8, 11, and 14-25 are now pending in this patent application. Pursuant to the Examiner's objection, the Abstract has been amended in order to define the substituents of Formula (I). Reconsideration and withdrawal of the rejections of this application are respectfully requested in view of the above amendments, and further, in view of the following remarks.

Preliminarily, Applicants note that the requirement for restriction was deemed proper and, therefore, made final. Accordingly, claims 12 and 13 of Group II, have been canceled without prejudice to their further prosecution in one or more continuation or divisional applications.

Claims 1 and 2 have been amended in order to properly place punctuation throughout the claims. Claim 2 now ends in a period rather than a semi-colon. In addition, a space has been placed between "aC₅₋₇". Claim 1 now contains only one period, and is, therefore, in the form of a complete sentence. Reconsideration and withdrawal of the objections to these claims are respectfully requested.

Claims 1-10 and 14-16 have been rejected under 35 U.S.C. §112, second paragraph, as being indefinite. Specifically, the Action suggests that as written, the "term 'optionally' can be interpreted as applying only to the first and named member of the Markush group in which 'optionally' appears or may be interpreted as applying to the whole Markush group and this term is therefore ambiguous . . .". Further, in claims 15 and 16, the Action asserts that it is "not clear if the material in parenthesis are meant to be examples or definitions". Reconsideration and withdrawal of the rejection are respectfully solicited.

A

Serial No.: 08/450,437
Group Art Unit No.: 1207

The term "optionally", throughout claim 1, has been amended in order to clarify which members of the Markush group are referred to by the term. New claims 17-25 have been drafted with this rejection in mind. Applicants submit that the claims are definite under Section 112, second paragraph.

With regard to the use of parenthesis in claims 15 and 16, Applicants submit that the terms in parenthesis are clearly examples of the broader disease states defined in the claims. Since it appears clear to Applicants that this is the case, no amendment is considered necessary.

Applicants submit that, based upon the above amendments and explanations, claims 1-10 and 14-16 are in proper condition for allowance under Section 112, second paragraph.

Claims 9-11 have been objected to under 37 C.F.R. §1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Claims 9 and 10 have been canceled. With regard to claim 11, Applicants submit that all of the species claimed therein are part of the genus as defined in claim 1. Therefore, this objection of claim 11 appears incorrect, since claim 11 does further limit the genus of claim 1. Clarification is respectfully requested if Applicants' interpretation of the objection is incorrect.

Claims 1-11 and 14-16 have been rejected under 35 U.S.C §102(b), as being anticipated by Mishra et al., *Indian J. Parm. Sci.*, 50(5), pp. 269-271 (1988), and CA 110:185561 (1988) ("Mishra"). In particular, the Action asserts that Mishra discloses a compound for treating inflammation "which is identical to applicants (sic) quinolines wherein applicants (sic) group R₅ is phenyl, R₃ and R₄ are hydrogen, X is oxygen and R and R₁ are hydrogen and Ar is substituted aromatic". Reconsideration and withdrawal of this rejection are requested.

Applicants respectfully assert that the Action mistakenly characterizes their invention. A close reading of the broadest genus, as claimed in claim 1, clarifies that for the instant invention, R can never be hydrogen. Therefore, there is no overlap between Mishra and the instant invention. Since Mishra does not disclose each and every element of claims 1-11 and 14-16, the claims cannot be said to be anticipated by Mishra. Therefore, reconsideration and withdrawal of the rejection of claims 1-11 and 14-16 under §102(b) are requested.


New claims 17-25 have been added, and are directed to specific embodiments of this invention. Support for the addition of new claims 17-25 is found in the claims and specification as originally filed. No new matter has been added under these claims.

In view of the foregoing, favorable reconsideration of claims 1-8, 11 and 14-16,

Serial No.: 08/450,437
Group Art Unit No.: 1207

favorable consideration of new claims 17-25, and allowance of this application with claims 1-8, 11 and 14-25, are earnestly solicited.

Respectfully submitted,

A handwritten signature in cursive script, reading "Nora Stein-Fernandez". The signature is fluid and elegant, with the first and last names being more prominent than the middle name.

Nora Stein-Fernandez
Attorney for Applicants
Registration No. 36,689

SMITHKLINE BEECHAM CORPORATION
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5044
Facsimile (610) 270-5090
n:\nsf\patapps\P30958C2\amend.doc